RXP470.1 (RXP-470) is a potent and selective inhibitor of MMP-12 (Ki = 0.2 nM against human MMP-12), with 2–4 orders of magnitude lower potency against other MMPs; it significantly reduces the cross-sectional area of atherosclerotic plaques in mice, decreases plaque complexity, increases the smooth muscle cell-to-macrophage ratio, reduces macrophage apoptosis, increases fibrous cap thickness, reduces necrotic core size, and lowers the incidence of calcification.